No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer

European Journal of Cancer

Volumn 36, Issue 13, 2000, Pages 1695-1705

  Reijerkerk, A ^a   Voest, E E ^a   Gebbink, M F B G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Angiostatin; Endostatin; Extracellular matrix; Fibrin; Metastasis; Plasminogen; TAFI; Therapeutic strategies

Indexed keywords

ANGIOSTATIN; ANTIFIBRINOLYTIC AGENT; ENDOSTATIN; FIBRIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRANEXAMIC ACID;

ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CELL ADHESION; CELL MIGRATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANTINEOPLASTIC AGENTS; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; COLLAGEN; ENDOSTATINS; HUMANS; LYSINE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033852790     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00157-X     Document Type: Article

References (144)

1. Folkman J. Fighting cancer by attacking its blood supply. Sci. Am. 275:1996;150-154.
2. Dvorak H.F. Abnormalities of hemostasis in malignancy. Colman R.W., Hirsch J., Marder V.J., Saltzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1994;1238-1254 JB Lipincott, Philadelphia.
3. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 285:1999;1926-1928.
4. O'Reilly M.S., Holmgren L., Shing Y.et al. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell. 79:1994;315-328.
5. Browder T., Folkman J., Pirie-Shepherd S. The haemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275:2000;1521-1524.
6. Dvorak H.F., Senger D.R., Dvorak A.M. Fibrin as a component of the tumor stroma. origins and biological significance Cancer Metastasis Rev. 2:1983;41-73.
7. Dvorak H.F. Tumors. wounds that do not heal. Similarities between tumor stroma generation and wound healing N. Engl. J. Med. 315:1986;1650-1659.
8. Zucker S., Mirza H., Conner C.E.et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells. conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation Int. J. Cancer. 75:1998;780-786.
9. Folkman J. Tumor angiogenesis and tissue factor. Nat. Med. 2:1996;167-168.
10. Ruf W., Mueller B.M. Tissue factor in cancer angiogenesis and metastasis. Curr. Opin. Hematol. 3:1996;379-384.
11. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
12. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis. insights into potential mechanisms of action and clinical development J. Clin. Invest. 103:1999;1227-1230.
13. Isik F.F., Gibran N.S., Jang Y.C., Sandell L., Schwartz S.M. Vitronectin decreases microvascular endothelial cell apoptosis. J. Cell Physiol. 175:1998;149-155.
14. Brooks P.C., Montgomery A.M., Rosenfeld M.et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
15. Stromblad S., Becker J.C., Yebra M., Brooks P.C., Cheresh D.A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J. Clin. Invest. 98:1996;426-433.
16. Flaumenhaft R., Abe M., Mignatti P., Rifkin D.B. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells. regulation of plasminogen activator activity J. Cell Biol. 118:1992;901-909.
17. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:1991;902-906.
18. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110:1997;2293-2302.
19. Del Rosso M., Fibbi G., Dini G.et al. Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J. Invest. Dermatol. 94:1990;310-316.
20. MacDonald T.J., DeClerck Y.A., Laug W.E. Urokinase induces receptor mediated brain tumor cell migration and invasion. J. Neurooncol. 40:1998;215-226.
21. Miles L.A., Plow E.F. Binding and activation of plasminogen on the platelet surface. J. Biol. Chem. 260:1985;4303-4311.
22. Correc P., Fondaneche M.C., Bracke M., Burtin P. The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines. Int. J. Cancer. 46:1990;745-750.
23. Vassalli J.D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100:1985;86-92.
24. Hajjar K.A., Hamel N.M., Harpel P.C., Nachman R.L. Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest. 80:1987;1712-1719.
25. Cesarman G.M., Guevara C.A., Hajjar K.A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269:1994;21198. -21203.
26. Redlitz A., Fowler B.J., Plow E.F., Miles L.A. The role of an enolase-related molecule in plasminogen binding to cells. Eur J. Biochem. 227:1995;407-415.
27. Miles L.A., Dahlberg C.M., Plescia J.et al. Role of cell-surface lysines in plasminogen binding to cells. identification of alpha-enolase as a candidate plasminogen receptor Biochemistry. 30:1991;1682-1691.
28. Kost C., Stuber W., Ehrlich H.J., Pannekoek H., Preissner K.T. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J. Biol. Chem. 267:1992;12098. -12105.
29. Moser T.L., Enghild J.J., Pizzo S.V., Stack M.S. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J. Biol. Chem. 268:1993;18917. -18923.
30. Stack M.S., Moser T.L., Pizzo S.V. Binding of human plasminogen to basement-membrane (type IV) collagen. Biochem. J. 284:1992;103-108.
31. Sprengers E.D., Kluft C. Plasminogen activator inhibitors. Blood. 69:1987;381-387.
32. Moroi M., Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol. Chem. 251:1976;5956-5965.
33. Holmes W.E., Nelles L., Lijnen H.R., Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J. Biol. Chem. 262:1987;1659-1664.
34. Suenson E., Lutzen O., Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J. Biochem. 140:1984;513-522.
35. Fleury V., Loyau S., Lijnen H.R., Nieuwenhuizen W., Angles-Cano E. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. Eur J. Biochem. 216:1993;549-556.
36. Fleury V., Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces. the role of carboxy-terminal lysines Biochemistry. 30:1991;7630-7638.
37. Wang W., Boffa M.B., Bajzar L., Walker J.B., Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 273:1998;27176. -27181.
38. Nesheim M., Wang W., Boffa M.et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 78:1997;386-391.
39. Nesheim M.E. TAFI. Fibrinolysis & Proteolysis. 13:1999;72-77.
40. Campbell W., Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res. Commun. 162:1989;933-939.
41. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270:1995;14477. -14484.
42. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27:1989;277-285.
43. Tan A.K., Eaton D.L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 34:1995;5811-5816.
44. Wang W., Hendriks D.F., Scharpe S.S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 269:1994;15937. -15944.
45. Mao S.S., Cooper C.M., Wood T., Shafer J.A., Gardell S.J., Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J. Biol. Chem. 274:1999;35046. -35052.
46. Nesheim M., Wang W., Boffa M.et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 78:1997;386-391.
47. Hosaka Y., Takahashi Y., Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost. 79:1998;371-377.
48. Calnek D.S., Grinnell B.W. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res. 238:1998;294-298.
49. Refino A., Schmitt D., Pater C., Eaton D., Bunting S. A carboxypeptidase inhibitor markedly improves the potency of t-PA in vivo. Fibrinolysis Proteolysis. 12(Suppl. 1):1999;29.
50. Ignar D.M., Andrews J.L., Witherspoon S.M.et al. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp Metastasis. 16:1998;9-20.
51. Min H.Y., Doyle L.V., Vitt C.R.et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56:1996;2428-2433.
52. Lu H., Mabilat C., Yeh P.et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett. 380:1996;21-24.
53. Lu H., Yeh P., Guitton J.D.et al. Blockage of the urokinase receptor on the cell surface. construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin FEBS Lett. 356:1994;56-59.
54. Koolwijk P., van Erck M.G., de Vree W.J.et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 132:1996;1177-1188.
55. Jankun J., Keck R.W., Skrzypczak-Jankun E., Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 57:1997;559-563.
56. Billstrom A., Hartley-Asp B., Lecander I., Batra S., Astedt B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int. J. Cancer. 61:1995;542-547.
57. Kobayashi H., Gotoh J., Shinohara H., Moniwa N., Terao T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost. 71:1994;474-480.
58. Ossowski L., Russo-Payne H., Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies. the effect on dissemination of a human tumor in the nude mouse Cancer Res. 51:1991;274-281.
59. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:1983;611-619.
60. Evans C.P., Elfman F., Parangi S.et al. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. 57:1997;3594-3599.
61. Mignatti P., Tsuboi R., Robbins E., Rifkin D.B. In vitro angiogenesis on the human amniotic membrane. requirement for basic fibroblast growth factor-induced proteinases J. Cell Biol. 108:1989;671-682.
62. Sato Y., Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells. activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture J. Cell Biol. 109:1989;309-315.
63. Uetsuji S., Yamamura M., Takai S., Hioki K., Yamamoto M. Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today. 22:1992;439-442.
64. Ambrus J.L., Ambrus C.M., Toumbis C.A.et al. Studies on tumor induced angiogenesis. J. Med. 22:1991;355-369.
65. Kodama Y., Tanaka K. Effect of tranexamic acid on the growth and metastasis of V2 carcinoma in rabbits. Gann. 72:1981;411-416.
66. Tanaka N., Ogawa H., Tanaka K., Kinjo M., Kohga S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invas. Metastasis. 1:1981;149-157.
67. Iwakawa A., Tanaka K. Effect of fibrinolysis inhibitor and chemotherapeutics on the growth of human cancers transplanted into nude mice and in tissue culture. Invas. Metastasis. 2:1982;232-248.
68. Astedt B., Trope C. Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis. Experientia. 36:1980;679-680.
69. Kikuchi Y., Kizawa I., Oomori K.et al. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res. 47:1987;592-596.
70. Sawaya R., Mandybur T., Ormsby I., Tew J.M. Jr. Antifibrinolytic therapy of experimentally grown malignant brain tumors. J. Neurosurg. 64:1986;263-268.
71. Ogawa H., Sekiguchi F., Tanaka N.et al. Effect of antifibrinolysis treatment on human cancer in nude mice. Anticancer Res. 2:1982;339-344.
72. Sigurdsson K., Johnsson J.E., Trope C. Tranexamic acid for the treatment of advanced ovarian carcinoma. Acta Obstet Gynecol Scand. 62:1983;265-266.
73. Kikuchi Y., Kizawa I., Oomori K., Matsuda M., Kato K. Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites. Acta Obstet Gynecol Scand. 65:1986;453-456.
74. Astedt B., Glifberg I., Mattsson W., Trope C. Arrest of growth of ovarian tumor by tranexamic acid. JAMA. 238:1977;154-155.
75. Astedt B., Mattsson W., Trope C. Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. Acta Med Scand. 201:1977;491-493.
76. Bramsen T. Effect of tranexamic acid on choroidal melanoma. Acta Ophthalmol. 56:1978;264-269.
77. Serdengecti S., Buyukunal E., Molinas N.et al. Overall survival results of non-small cell lung cancer patients. chemotherapy alone versus chemotherapy with combined immunomodulation Chemioterapia. 7:1988;122-126.
78. Soma H., Sashida T., Yoshida M., Miyashita T., Nakamura A. Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid). Acta Obstet Gynecol Scand. 59:1980;285-287.
79. Petrelli N.J., Markus G., Herrera L., Corasanti J., Mittelman A. Aminocaproic acid (AMICAR) in advanced colorectal carcinoma. J. Surg Oncol. 33:1986;109-111.
80. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:1996;689-692.
81. Sim B.K., O'Reilly M.S., Liang H., et al A. recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57:1997;1329-1334.
82. Cao Y., Chen A., An S.S.A.et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 272:1997;22924. -22928.
83. Cao Y., Ji R.W., Davidson D.et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271:1996;29461. -29467.
84. O'Reilly M.S., Holmgren L., Shing Y.et al. Angiostatin. a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth Cold Spring Harb Symp Quant Biol. 59:1994;471. -82; 471-482.
85. Wu Z., O'Reilly M.S., Folkman J., Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236:1997;651-654.
86. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
87. Dhanabal M., Ramchandran R., Volk R.et al. Endostatin. yeast production, mutants, and antitumor effect in renal cell carcinoma Cancer Res. 59:1999;189-197.
88. Yoon S.S., Eto H., Lin C.M.et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 59:1999;6251-6256.
89. Sasaki T., Larsson H., Kreuger J.et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 18:1999;6240-6248.
90. O'Reilly M.S., Boehm T., Shing Y.et al. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285.
91. Dhanabal M., Ramchandran R., Waterman M.J.et al. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274:1999;11721. -11726.
92. Brown D.C., Purushotham A.D., George W.D. Inhibition of pulmonary tumor seeding by antiplatelet and fibrinolytic therapy in an animal experimental model. J. Surg Oncol. 55:1994;154-159.
93. Purushotham A.D., Brown D.C., McCulloch P., Choy A., George W.D. Streptokinase inhibits pulmonary tumor seeding in an animal experimental model. J. Surg Oncol. 57:1994;3. -7.
94. Blanco-Aparicio C., Molina M.A., Fernandez-Salas E.et al. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J. Biol. Chem. 273:1998;12370. -12377.
95. Burtin P., Zhang S., Schauffler J.et al. Visualization of the plasmin receptor on sections of human mammary carcinoma cells. Int. J. Cancer. 53:1993;17-21.
96. Tran-Thang C., Vouillamoz D., Kruithof E.K., Sordat B. Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. J. Cell Physiol. 161:1994;285-292.
97. Boffa M.B., Wang W., Bajzar L., Nesheim M.E. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J. Biol. Chem. 273:1998;2127-2135.
98. Drixler TA, Borel Rinkes IHM, Ritchie ED, van Vroonhoven TJMV, Gebbink MFBG, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000, 60, 1761-1765.
99. Ossowski L. Invasion of connective tissue by human carcinoma cell lines. requirement for urokinase, urokinase receptor, and interstitial collagenase Cancer Res. 52:1992;6754-6760.
100. Sugarbaker E.V., Thornthwaite J., Khokha R. Inhibitory effect of a primary tumor on metastases. Day S.B., Myers W.P.L., Stansly P., Garattini S., Lewis M.G. Progress on Cancer Research and Therapy. 1977;227-240 Raven Press, New York.
101. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
102. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases. balanced proliferation and apoptosis in the presence of angiogenesis suppression Nature Med. 1:1995;149-153.
103. Gately S., Twardowski P., Stack M.S.et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56:1996;4887-4890.
104. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 274:1999;29568. -29571.
105. Lijnen H.R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry. 37:1998;4699-4702.
106. Patterson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B type IV collagenase (MMP-9). J. Biol. Chem. 272:1997;28823. -28825.
107. Stathakis P., Fitzgerald M., Matthias L.J., Chesterman C.N., Hogg P.J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem. 272:1997;20641. -20645.
108. Dong Z., Kumar R., Yang X., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88:1997;801-810.
109. Moser T.L., Stack M.S., Asplin I.et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA. 96:1999;2811-2816.
110. Kost C., Benner K., Stockmann A., Linder D., Preissner K.T. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J. Biochem. 236:1996;682-688.
111. Claesson-Welsh L., Welsh M., Ito N.et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA. 95:1998;5579-5583.
112. Stack M.S., Gately S., Bafetti L.M., Enghild J.J., Soff G.A. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 340:1999;77-84.
113. Sugiyama N., Iwamoto M., Abiko Y. Effects of kringles derived from human plasminogen on fibrinolysis in vitro. Thromb Res. 47:1987;459-468.
114. Fan Z., Larson P.J., Bognacki J.et al. Tissue factor regulates plasminogen binding and activation. Blood. 91:1998;1987-1998.
115. Schuppan D., Cramer T., Bauer M.et al. Hepatocytes as a source of collagen type XVIII endostatin. Lancet. 352:1998;879-880.
116. Chang Z., Choon A., Friedl A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am. J. Pathol. 155:1999;71-76.
117. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 59:1999;6052-6056.
118. Tandker L., Schrader M., Kanse S.M.et al. Isolation and characterization of the circulating form of human endostatin. FEBS Lett. 420:1997;129-133.
119. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
120. Hsu S.C., Volpert O.V., Steck P.A.et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 56:1996;5684-5691.
121. Rastinejad F., Polverini P.J., Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 56:1989;345-355.
122. Blei F., Wilson E.L., Mignatti P., Rifkin D.B. Mechanism of action of angiostatic steroids. suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis J. Cell Physiol. 155:1993;568-578.
123. Soff G.A., Sanderowitz J., Gately S.et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96:1995;2593-2600.
124. Pepper M.S., Belin D., Montesano R., Orci L., Vassalli J.D. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J. Cell Biol. 111:1990;743-755.
125. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis. a review Int. J. Cancer. 72:1997;1-22.
126. Bajou K., Noel A., Gerard R.D.et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4:1998;923-928.
127. Polverini P.J., DiPietro L.A., Dixit V.M., Hynes R.O., Lawler J. TSP-1 knockout mice showed delayed organization and prolonged neovascularization of skin wounds. FASEB J. 9:1995;A227.
128. Bardos H., Molnar P., Csecsei G., Adany R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis. 7:1996;36-548.
129. Egyud L.G., Lipinski B. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. Med Hypotheses. 36:1991;336-340.
130. Ge M., Tang G., Ryan T.J., Malik A.B. Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis. J. Clin. Invest. 90:1992;2508-2516.
131. Reinartz J., Schafer B., Batrla R., Klein C.E., Kramer M.D. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res. 220:1995;274-282.
132. Sugimura M., Kobayashi H., Terao T. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells. Gynecol Oncol. 52:1994;337-346.
133. Silverman P., Goldsmith G.H. Jr., Spitzer T.R., Rehmus E.H., Berger N.A. Effect of tumor necrosis factor on the human fibrinolytic system. J. Clin. Oncol. 8:1990;468-475.
134. Hinsbergh V.W., van Bauer K.A., Kooistra T.et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood. 76:1990;2284-2289.
135. Merryman P., Tannenbaum S.H., Gralnick H.R.et al. Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-gamma, and/or melphalan. Thromb Haemost. 77:1997;53-56.
136. DeClerck Y.A., Perez N., Shimada H.et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:1992;701-708.
137. Logan T.F., Virji M.A., Gooding W.E.et al. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor. J. Natl. Cancer Inst. 84:1992;1802-1810.
138. Roblin R.O., Hammond M.E., Bensky N.D.et al. Generation of macrophage migration inhibitory activity by plasminogen activators. Proc. Natl. Acad. Sci. USA. 74:1977;1570-1574.
139. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 352:1998;1775-1777.
140. Ramchandran R., Dhanabal M., Volk R.et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV. comparison to endostatin Biochem. Biophys. Res. Commun. 255:1999;735-739.
141. Kamphaus G.D., Colorado P.C., Panka D.J.et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275:2000;1209-1215.
142. Rhim T.Y., Park C.S., Kim E., Kim S.S. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem. Biophys. Res. Commun. 252:1998;513-516.
143. Sheng S., Truong B., Fredrickson D., Wu R., Pardee A.B., Sager R. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc. Natl. Acad. Sci. USA. 95:1998;499-504.
144. Zhang M., Volpert O., Shi Y.H., Bouck N. Maspin is an angiogenesis inhibitor. Nature Med. 6:2000;196-199.